HOUSTON--(BUSINESS WIRE)--The National Institute for Clinical Excellence (NICE), a UK government-funded, non-departmental public body that aims to establish guidelines for clinical best practice, issued its recommendation for the National Health Service (NHS) to use Qbtech’s industry-leading objective tests to improve diagnostic wait times for children and youth, age six to 17.

休斯顿--（商业新闻短讯）--国家临床卓越研究所（NICE）是一家由英国政府资助的非部门公共机构，旨在制定临床最佳实践指南，它向国家卫生服务局（NHS）发布了建议，建议使用Qbtech业界领先的客观测试来改善6至17岁儿童和青少年的诊断等待时间。

The approval for using QbTest alongside traditional diagnostic methods enables more children to get diagnosed within six months of their initial assessment, addressing the long waiting periods many families are experiencing..

与传统诊断方法一起使用QbTest的批准使更多的儿童能够在初次评估后的六个月内得到诊断，从而解决了许多家庭正在经历的漫长等待期。。

Results from the AQUA clinical trial found that using the QbTest alongside a standard clinical assessment for ADHD resulted in faster diagnostic decisions being made for a more significant proportion of people within six months of their first assessment appointment when QbTest results were available, compared with when they were not.

AQUA临床试验的结果发现，使用QbTest和ADHD的标准临床评估可以在QbTest结果可用的情况下，在第一次评估预约的六个月内，与没有QbTest结果的情况相比，对更大比例的人做出更快的诊断决定。

It also resulted in clinicians being able to rule out ADHD in more cases..

这也导致临床医生能够在更多情况下排除ADHD。。

“The evidence we have to date, further cemented by the recent NICE recommendation to the NHS, highlights the importance of objective ADHD testing in improving overall ADHD care,” shared Dr. Angela LaRosa, a Charleston-based developmental and behavioral pediatrician. “As a specialist in developmental and behavioral pediatrics, incorporating objective ADHD assessments in my practice has been crucial for increasing access to care, and we now have better data for making informed care decisions, including treatment optimization and monitoring.'.

“最近NICE向NHS提出的建议进一步巩固了我们迄今为止的证据，突显了客观ADHD测试在改善整体ADHD护理中的重要性，”位于查尔斯顿的发育和行为儿科医生AngelaLarosa博士分享道。“作为发育和行为儿科的专家，在我的实践中纳入客观的ADHD评估对于增加获得护理的机会至关重要，我们现在有更好的数据来做出明智的护理决策，包括治疗优化和监测。”。

QbTest is an FDA-cleared, market-leading computer-based test with motion tracking that measures core ADHD symptoms—inattention, impulsivity, and hyperactivity. The results are analyzed and presented in an easy-to-read visual report comparing them to a normative control group of the same age and sex at birth who do not have ADHD..

QbTest是一项FDA批准的、市场领先的基于计算机的运动跟踪测试，可测量注意力不集中、冲动和多动症的核心症状。将结果进行分析并以易于阅读的视觉报告形式呈现，将其与出生时相同年龄和性别且没有ADHD的规范对照组进行比较。。

“ADHD diagnosis rates are rising globally, with the CDC reporting a 16% increase from 2016 to 2022,” said Mikkel Hansen, Chief Medical Officer at Qbtech. “The increase in demand has put a severe strain on healthcare systems, leading to significant delays in diagnosis that are having far-reaching effects on children and their families.

Qbtech首席医疗官米克尔·汉森（MikkelHansen）表示：“ADHD的诊断率在全球范围内呈上升趋势，CDC报告从2016年到2022年增长了16%。”。“需求的增加给医疗保健系统带来了严重的压力，导致诊断的严重延误，这对儿童及其家庭产生了深远的影响。

Our objective tests add necessary safeguards to the diagnostic process and enable clinicians to complete a comprehensive assessment effectively and efficiently. We’re honored to be recognized by NICE and excited to further our work with the NHS to improve access to ADHD care in the UK and with similar organizations worldwide.”.

我们的客观测试为诊断过程增加了必要的保障措施，使临床医生能够有效地完成全面评估。我们很荣幸得到NICE的认可，并很高兴与NHS进一步合作，以改善英国和全球类似组织获得ADHD护理的机会。”。

Qbtech’s objective ADHD testing technology is used by more than 12,000 clinicians across 44 states in the U.S. and at the national level by organizations such as the NHS in England in over 120 sites. The company has been documented in more than 40 independent studies, showing benefits across the patient care pathway, including improved access to care, elevated clinician confidence, better identification of treatment effects than self-rating, and standardization of care across multiple disciplines..

Qbtech的客观ADHD测试技术在美国44个州的12000多名临床医生中使用，在国家层面上由英国NHS等组织在120多个地点使用。该公司已被记录在40多项独立研究中，显示了整个患者护理途径的益处，包括改善了获得护理的机会，提高了临床医生的信心，比自我评估更好地识别治疗效果，以及跨多个学科的护理标准化。。

About Qbtech

关于Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com..

Qbtech成立于2002年，是一家瑞典私营公司，开发了领先的解决方案和产品，用于改善ADHD患者的识别，诊断，治疗和随访。Qbtech在14个国家开展业务，并在斯德哥尔摩、休斯顿和伦敦设有办事处。Qbtech是一家因其创新而备受赞誉的获奖公司，最近一次获得2022年HSJ合作奖，表彰其“与NHS的最佳心理健康合作伙伴关系”有关Qbtech的更多信息，请访问www.Qbtech.com。。